CSL reported strong profit growth for the past year, but has launched several strategic initiatives, including separating its vaccine business into a standalone company and reducing the number of plasma collection centres in the US.
CSL launches strategic initiatives with planned separation of Seqirus
August 20, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
LTR Pharma says new study confirms faster onset of intranasal treatment
August 20, 2025 - - BioPharma -
Neurizon's NUZ-001 OLE study demonstrates long-term safety and efficacy signals
August 20, 2025 - - Australian Biotech -
US FDA grants orphan drug designation to Invion's INV043
August 20, 2025 - - Australian Biotech -
AI added to the work of HTA Review Implementation Advisory Group
August 20, 2025 - - Latest News -
CSL launches strategic initiatives with planned separation of Seqirus
August 20, 2025 - - Latest News -
Former Queensland Premier appointed to chair Brandon BioCatalyst
August 19, 2025 - - Australian Biotech -
Lilly launches new initiative with Monash University to improve gaps in obesity management
August 18, 2025 - - Latest News